Now in its second edition, this comprehensive handbook provides a state-of-the-art overview of recent advances in drug and non-drug therapies for obesity and diabetes. It also addresses major comorbidities, covering topics such as, cardiovascular diseases, renal and neuropsychiatric disorders, appetite control and micro RNAs. Special attention is also devoted to pediatric care, including the latest recommendations for therapy and prevention. Obesity and type 2 diabetes are among the top global health-care budget concerns worldwide and impact professional practice at all levels: in hospitals, clinics and physicians' offices alike. They prominently feature in headlines, and virtually no family, community or country is exempt from their protean, deleterious consequences. Furthermore, given the multiple intersections in their pathways, they often go hand in hand. The good news is that scientific advances in all fields, including genomics, metabolomics, lipidomics and microbiomics, are increasing our understanding of these two disease areas. At the same time, artificial intelligence, machine learning, mobile health and advanced implantable and external devices are rendering prevention and management more available, safe and cost-effective. In addition, bariatric and metabolic surgery has evolved from a niche specialty to an officially endorsed option for several modalities of obesity and diabetes. This book presents the latest lifestyle, pharmacological, surgical and non-surgical treatment options, including endoscopic intervention and cell therapy. Objectively reviewing natural and artificial sweeteners and critically examining issues such as public health initiatives, government mandated taxes for unhealthy foods and environmental planning, no stone is left unturned in gathering the latest practical information. As such, the book will appeal to seasoned specialists, as well as students and healthcare professionals in training.

Obesity is currently regarded as one of the major health challenges of the developed world. Excess body weight is an important risk factor for morbidity and mortality from cardiovascular diseases, diabetes, cancer, musculoskeletal disorders and even psychiatric problems and is estimated to cause nearly 3 million deaths per year worldwide. Obesity is not necessarily associated with comorbidities: there are indeed metabolically healthy obese individuals. Thus, we need to consider individuals presenting simple with obesity separately from those at risk of developing or who have already developed complex clinical states potentially leading to disability. Comorbidities can tip the balance of independence in patients who already have functional limitations mainly due to the excess of mass itself or who develop conditions such as diabetes, cardiovascular conditions, non-alcoholic fatty liver disease, where an abnormal metabolism of adipose tissue prevails. Morbid obesity with comorbidities leading to disability represents a real social and economic burden for National Health Systems worldwide. The presence of multiple and associated comorbidities often represents an obstacle to being admitted to hospitals for the treatment of metabolic diseases. On the other hand, clinical units with optimal standards for the treatment of pathological conditions in normal-weight patients are often structurally and technologically inadequate for the care of patients with extreme obesity. The aim of this book is to focus on the pathophysiological and rehabilitative aspects of disabling obesity, highlighting multidisciplinary rehabilitation interventions as key to counteracting the disabling aspects of complicated obesity.

Now in its second edition, this comprehensive handbook provides a state-of-the-art overview of recent advances in drug and non-drug therapies for obesity and diabetes. It also addresses major comorbidities, covering topics such as, cardiovascular diseases, renal and neuropsychiatric disorders, appetite control and micro RNAs. Special attention is also devoted to pediatric care, including the latest recommendations for therapy and prevention. Obesity and type 2 diabetes are among the top global health-care budget concerns worldwide and impact professional practice at all levels: in hospitals, clinics and physicians' offices alike. They prominently feature in headlines, and virtually no family, community or country is exempt from their protean, deleterious consequences. Furthermore, given the multiple intersections in their pathways, they often go hand in hand. The good news is that scientific advances in all fields, including genomics, metabolomics, lipidomics and microbiomics, are increasing our understanding of these two disease areas. At the same time, artificial intelligence, machine learning, mobile health and advanced implantable and external devices are rendering prevention and management more available, safe and cost-effective. In addition, bariatric and metabolic surgery has evolved from a niche specialty to an officially endorsed option for several modalities of obesity and diabetes. This book presents the latest lifestyle, pharmacological, surgical and non-surgical treatment options, including endoscopic intervention and cell therapy. Objectively reviewing natural and artificial sweeteners and critically examining issues such as public health initiatives, government mandated taxes for unhealthy foods and environmental planning, no stone is left unturned in gathering the latest practical information. As such, the book will appeal to seasoned specialists, as well as students and healthcare professionals in training.

Obesity is currently regarded as one of the major health challenges of the developed world. Excess body weight is an important risk factor for morbidity and mortality from cardiovascular diseases, diabetes, cancer, musculoskeletal disorders and even psychiatric problems and is estimated to cause nearly 3 million deaths per year worldwide. Obesity is not necessarily associated with comorbidities: there are indeed metabolically healthy obese individuals. Thus, we need to consider individuals presenting simple with obesity separately from those at risk of developing or who have already developed complex clinical states potentially leading to disability. Comorbidities can tip the balance of independence in patients who already have functional limitations mainly due to the excess of mass itself or who develop conditions such as diabetes, cardiovascular conditions, non-alcoholic fatty liver disease, where an abnormal metabolism of adipose tissue prevails. Morbid obesity with comorbidities leading to disability represents a real social and economic burden for National Health Systems worldwide. The presence of multiple and associated comorbidities often represents an obstacle to being admitted to hospitals for the treatment of metabolic diseases. On the other hand, clinical units with optimal standards for the treatment of pathological conditions in normal-weight patients are often structurally and technologically inadequate for the care of patients with extreme obesity. The aim of this book is to focus on the pathophysiological and rehabilitative aspects of disabling obesity, highlighting multidisciplinary rehabilitation interventions as key to counteracting the disabling aspects of complicated obesity.

This timely and clinically oriented book uniquely addresses the entire spectrum of treatment for severe obesity and diabetes. It thoroughly examines all aspects from robotic surgery to cell therapy, from the latest antidiabetic drugs to endoscopic procedures and devices, from appetite-inhibiting signals and nutrients to gastric arterial embolization. It offers objective and authoritative information for practicing professionals; not only are successful interventions discussed and updated, but cutting-edge and experimental pathways are also anticipated. Obesity is the foremost nutritional challenge worldwide. Its companion is type-2 diabetes, the most prevalent metabolic disease. Together they represent the diabesity epidemic, which is draining resources, overwhelming healthcare facilities, and impacting life expectancy and quality of life everywhere. No country has been spared, and most medical specialties have been affected. Many books focus on the surgical options for obesity and diabetes, namely bariatric and metabolic operations. Information on the clinical and pharmacological treatment is also available, conveyed by standard texts on internal medicine and endocrinology. Yet endoscopic maneuvers and prostheses, cell therapy for diabetes, and other innovative approaches are hard to come by, as conventional texts overlook such therapies. This timely publication bridges the gaps between all different therapeutic options, also covering advances in the conservative, surgical and parasurgical domains. This book will appeal to seasoned specialists, students and healthcare professionals in training alike.

Microbiome and Metabolome in Diagnosis, Therapy, and Other Strategic Applications is the first book to simultaneously cover the microbiome and the metabolome in relevant clinical conditions. In a pioneering fashion, it addresses not only the classic intestinal environment, but also the oral, gastric, lung, skin and vaginal microbiome that is in line with the latest investigations. Nonbacterial microbiomes, such as fungi and viruses are not overlooked, and the plasma microbiome is also discussed. As plasma, brain, placenta, tumor cells, and other sterile fluids and tissues, are increasingly recognized to potentially host a microbiome, albeit a limited one, this is a timely resource. The book's editors were fortunate to have the input of renowned collaborators from nearly all continents. This is truly an international effort that brings the latest in the field to students and professionals alike.

Precision Medicine for Investigators, Practitioners and Providers addresses the needs of investigators by covering the topic as an umbrella concept, from new drug trials to wearable diagnostic devices, and from pediatrics to psychiatry in a manner that is up-to-date and authoritative. Sections include broad coverage of concerning disease groups and ancillary information about techniques, resources and consequences. Moreover, each chapter follows a structured blueprint, so that multiple, essential items are not overlooked. Instead of simply concentrating on a limited number of extensive and pedantic coverages, scholarly diagrams are also included.

This timely and clinically oriented book uniquely addresses the entire spectrum of treatment for severe obesity and diabetes. It thoroughly examines all aspects from robotic surgery to cell therapy, from the latest antidiabetic drugs to endoscopic procedures and devices, from appetite-inhibiting signals and nutrients to gastric arterial embolization. It offers objective and authoritative information for practicing professionals; not only are successful interventions discussed and updated, but cutting-edge and experimental pathways are also anticipated. Obesity is the foremost nutritional challenge worldwide. Its companion is type-2 diabetes, the most prevalent metabolic disease. Together they represent the diabesity epidemic, which is draining resources, overwhelming healthcare facilities, and impacting life expectancy and quality of life everywhere. No country has been spared, and most medical specialties have been affected. Many books focus on the surgical options for obesity and diabetes, namely bariatric and metabolic operations. Information on the clinical and pharmacological treatment is also available, conveyed by standard texts on internal medicine and endocrinology. Yet endoscopic maneuvers and prostheses, cell therapy for diabetes, and other innovative approaches are hard to come by, as conventional texts overlook such therapies. This timely publication bridges the gaps between all different therapeutic options, also covering advances in the conservative, surgical and parasurgical domains. This book will appeal to seasoned specialists, students and healthcare professionals in training alike.